 |
InterPro: IPR018521 DNA topoisomerase I, active site
Protein matches
|
UniProtKB Matches: 230 proteins |
|
Accession
|
IPR018521 TopoI_AS |
Type
|
Active_site |
Signatures
|
|
InterPro Relationships
|
|
Found in
|
IPR001631 DNA topoisomerase I, C-terminal
IPR011010 DNA breaking-rejoining enzyme, catalytic core
IPR013499 DNA topoisomerase I, C-terminal, eukaryotic-type
IPR014727 DNA topoisomerase I, catalytic core, alpha/beta subdomain, eukaryotic-type
|
GO Term annotation
|
|
Process
|
GO:0006265 DNA topological change
|
|
Function
|
GO:0003677 DNA binding
GO:0003917 DNA topoisomerase type I activity
|
|
InterPro annotation
|
|
Entry Details in BioMart
|
Abstract
|
DNA topoisomerases regulate the number of topological links between two DNA strands (i.e. change the number of superhelical turns) by catalysing transient single- or double-strand breaks, crossing the strands through one another, then resealing the breaks. These enzymes have several functions: to remove DNA supercoils during transcription and DNA replication; for strand breakage during recombination; for chromosome condensation; and to disentangle intertwined DNA during mitosis [1, 2]. DNA topoisomerases are divided into two classes: type I enzymes (EC:5.99.1.2; topoisomerases I, III and V) break single-strand DNA, and type II enzymes (EC:5.99.1.3; topoisomerases II, IV and VI) break double-strand DNA [3]. Type I topoisomerases are ATP-independent enzymes (except for reverse gyrase), and can be subdivided according to their structure and reaction mechanisms: type IA (bacterial and archaeal topoisomerase I, topoisomerase III and reverse gyrase) and type IB (eukaryotic topoisomerase I and topoisomerase V). These enzymes are primarily responsible for relaxing positively and/or negatively supercoiled DNA, except for reverse gyrase, which can introduce positive supercoils into DNA. DNA topoisomerase I (EC:5.99.1.2) [4, 5, 6, 7] is one of the two types of enzyme that catalyze the interconversion of topological DNA isomers. Type I topoisomerases act by catalyzing the transient breakage of DNA, one strand at a time, and the subsequent rejoining of the strands. When a eukaryotic type 1 topoisomerase breaks a DNA backbone bond, it simultaneously forms a protein-DNA link where the hydroxyl group of a tyrosine residue is joined to a 3'-phosphate on DNA, at one end of the enzyme-severed DNA strand. In eukaryotes and poxvirus topoisomerases I, there are a number of conserved residues in the region around the active site tyrosine [6].
More information about this protein can be found at Protein of the Month: DNA Topoisomerase [8].
|
Structural links
|
|
Database links
|
|
Example proteins
|
O17966 DNA topoisomerase 1
P04786 DNA topoisomerase 1
P11387 DNA topoisomerase 1
P30189 DNA topoisomerase 1
Q04750 DNA topoisomerase 1
More proteins
Example Proteins Key
| InterPro entry accession number/name and structure databases |
Colour code |
| IPR014727 |
DNA topoisomerase I, catalytic core, alpha/beta subdomain, eukaryotic-type |
 |
| IPR011010 |
DNA breaking-rejoining enzyme, catalytic core |
 |
| IPR008336 |
DNA topoisomerase I, DNA binding, eukaryotic-type |
 |
| IPR018521 |
DNA topoisomerase I, active site |
 |
| IPR001631 |
DNA topoisomerase I, C-terminal |
 |
| IPR013030 |
DNA topoisomerase I, DNA binding, mixed alpha/beta motif, eukaryotic-type |
 |
| IPR013500 |
DNA topoisomerase I, catalytic core, eukaryotic-type |
 |
| IPR009054 |
DNA topoisomerases I, dispensable insert, eukaryotic-type |
 |
| IPR013499 |
DNA topoisomerase I, C-terminal, eukaryotic-type |
 |
| IPR014711 |
DNA topoisomerase I, catalytic core, alpha-helical subdomain, eukaryotic-type |
 |
|
PDB Chain |
 |
|
ModBase |
 |
|
CATH Domain |
 |
|
SWISS-MODEL |
 |
|
SCOP Domain |
 |
|
Additional Reading
|
|
Chrencik JE, Burgin AB, Pommier Y, Stewart L, Redinbo MR.
Structural impact of the leukemia drug 1-beta-D-arabinofuranosylcytosine (Ara-C) on the covalent human topoisomerase I-DNA complex.
J. Biol. Chem. 278 2003 12461-6
[PubMed: 12533542]
http://dx.doi.org/10.1074/jbc.M212930200
|
|
Chrencik JE, Staker BL, Burgin AB, Pourquier P, Pommier Y, Stewart L, Redinbo MR.
Mechanisms of camptothecin resistance by human topoisomerase I mutations.
J. Mol. Biol. 339 2004 773-84
[PubMed: 15165849]
http://dx.doi.org/10.1016/j.jmb.2004.03.077
|
|
Interthal H, Quigley PM, Hol WG, Champoux JJ.
The role of lysine 532 in the catalytic mechanism of human topoisomerase I.
J. Biol. Chem. 279 2004 2984-92
[PubMed: 14594810]
http://dx.doi.org/10.1074/jbc.M309959200
|
|
Staker BL, Feese MD, Cushman M, Pommier Y, Zembower D, Stewart L, Burgin AB.
Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex.
J. Med. Chem. 48 2005 2336-45
[PubMed: 15801827]
http://dx.doi.org/10.1021/jm049146p
|
|
Ioanoviciu A, Antony S, Pommier Y, Staker BL, Stewart L, Cushman M.
Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-enzyme-inhibitor complex as determined by X-ray crystallographic analysis.
J. Med. Chem. 48 2005 4803-14
[PubMed: 16033260]
http://dx.doi.org/10.1021/jm050076b
|
|
|
InterPro 23.1
|